### Atrial Fibrillation Catheter Ablation among Cancer Patients: Utilization Trends and In-Hospital Outcomes

Gilad Margolis MD<sup>a\*</sup>, Ofir Goldhaber MD<sup>a\*</sup>, Mark Kazatsker MD<sup>a</sup>, Ofer Kobo MD, Ariel

Roguin MD, PhD<sup>a</sup>, Eran Leshem MD, MHA<sup>a</sup>

<sup>a</sup> Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, The Ruth and Bruce

Rappaport Faculty of Medicine, Technion, Haifa, Israel

\* These authors have equally contributed to this work

Short title: Atrial fibrillation catheter ablation in cancer patients

#### **Corresponding author:**

Gilad Margolis MD,

Cardiac Electrophysiology Unit

Hillel Yaffe Medical Center, Hadera, Israel

Email: giladm@hymc.gov.il

Tel: +972-4-7744656, Fax. +972-4-7744182, Twitter handle: @GiladMargolis

Word count: 3165

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### ABSTRACT

**BACKGROUND:** Atrial fibrillation (AF) catheter ablation in cancer patients was evaluated in very few studies. We aimed to investigate trends of utilizations as well as inhospital outcomes of AF catheter ablation procedures among cancer patients, in a large inpatient US registry.

**METHODS AND RESULTS:** Using the National Inpatient Sample (NIS) database, patients who underwent AF catheter ablations in the US between 2012 and 2019 were identified using ICD-9/10 codes. Sociodemographic, clinical data, in-hospital procedures and outcomes as well as in-hospital mortality and length-of-stay (LOS) were collected. Baseline characteristics and in-hospital outcomes were compared between patients with and without cancer. An estimated total of 67915 patients underwent AF catheter ablation between 2012-2019 in the US. Of them, 950 (1.4%) had cancer diagnosis. Compared with non-cancer patients, patients with cancer were older, had higher Charlson Comorbidity Index, as well as CHA2DS2-VASc and ATRIA bleeding indices scores.

Higher rate of total complications was observed in cancer patients (10.5% vs 7.9, p<0.001) driven mainly by more bleeding and infectious complications. LOS was also significantly longer in cancer patients ( $4.9 \pm 5.8$  vs.  $2.7 \pm 3.0$  days, p<0.001). However, no significant differences in cardiac or neurological complications as well as in-hospital mortality rates were observed and were relatively low in both groups.

**CONCLUSIONS:** AF catheter ablation in cancer patients is associated with higher bleeding and infectious complication rates, but not with increased cardiac complications or in-hospital mortality rates in a nationwide, all-comer registry.

Key words: Atrial fibrillation, Catheter ablation outcomes, Cancer

#### Abbreviations:

AF	atrial fibrillation
AADs	antiarrhythmic drugs
CIED	cardiac implantable electronic device
Deyo-CCI	Deyo-Charlson Comorbidity Index
HCUP	Healthcare Cost and Utilization Project
ICD-10-CM/PCS	International Classification of Diseases, 10 <sup>th</sup> Revision, Clinical
	Modification/ Procedure Coding System
NIS	National Inpatient Sample
OR	odds ratio

#### **INTRODUCTION**

Atrial fibrillation (AF), is the most common sustained arrhythmia affecting 2-4% of the general population <sup>1</sup>. Cancer patients have an increased risk for developing AF, varying according to cancer type and stage <sup>2,3</sup>. Conversely, elevated cancer risk was observed among patients presenting with new-onset AF <sup>4</sup>. The exact pathophysiological mechanisms leading to AF in cancer patients are not yet fully understood. Suggested underlying mechanisms include similar risk factor profile for both AF and cancer development, inflammatory and paraneoplastic processes, autonomic nervous system imbalance or less commonly direct metastatic invasion of the tumor to the heart and surrounding tissues <sup>5</sup>. In addition, both medical and surgical cancer treatments were implicated as predisposing factors for AF development <sup>6,7</sup>.

Rhythm control for symptomatic AF in cancer patients portends a therapeutic challenge. Significant drug-drug interactions with concomitant anticancer therapy may preclude antiarrhythmic drugs (AADs) use <sup>8</sup>. Catheter ablation for AF is an effective and safe treatment strategy for symptomatic patients who do not benefit from AADs <sup>1</sup>. However, to

date, very few studies have evaluated AF catheter ablation among cancer patients <sup>9–14</sup>. Current guidelines and expert opinion positions papers do not provide clear recommendations for AF rhythm control in cancer patients and specific recommendations for catheter ablation are lacking <sup>1,5,15,16</sup>.

In this study we aimed to analyze trends of utilization and in-hospital outcomes of AF catheter ablation procedures among cancer patients using the US National In-Patient Sample (NIS) database.

#### **METHODS**

#### **Data Source**

The data were drawn from the NIS, the Healthcare Cost and Utilization Project, and the Agency for Healthcare Research and Quality. The NIS database includes only nonidentified data; Therefore, this study was deemed exempt from institutional review by the local Human Research Committee. The NIS is the largest collection of all-payer data on inpatient hospitalizations in the United States. The data set represents an  $\approx$ 20% stratified sample of all inpatient discharges from US hospitals <sup>17</sup>. This information includes patient-and hospital-level factors such as patient demographic characteristics, primary and secondary diagnoses and procedures, comorbidities, length of stay (LOS), hospital region, hospital teaching status, hospital bed size, and cost of hospitalization. National estimates can be calculated using the patient-and hospital-level sampling weights that are provided by the Healthcare Cost and Utilization Project.

For the purpose of this study, we obtained data for the years 2012 to 2019. The International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure

Coding System (ICD-10- CM/ PCS) was fully implemented from the last quarter of 2015 and thereafter for reporting diagnoses and procedures in the NIS database during the study period. From 2012 to 2015 (3<sup>rd</sup> quarter), hospitalizations were analyzed using ICD-9-CM/PCS coding system, and subsequently, with the ICD-10-CM/PCS coding system. For each index hospitalization, the database provides a principal discharge diagnosis and a maximum of 39 additional diagnoses, in addition to a maximum of 25 procedures.

#### **Study Population and Variables**

We identified patients aged  $\geq$ 18 years who had a primary diagnosis of atrial fibrillation using ICD-10-CM codes: I480, I481, I482, I4891 or ICD-9-CM code: 427.31 and also underwent Ablation using ICD-10-PCS codes: 02583ZZ, 02563ZZ, 02573ZZ, 025T3ZZ, 025S3ZZ or ICD-9-CM code:37.34. Using ICD-10-CM and ICD-9-CM codes (provided in detail in Table S1) we identified and excluded patients who had any of the following diagnoses: supraventricular tachycardia, atrioventricular nodal tachycardia, ventricular tachycardia, ventricular fibrillation, atrial flutter, ventricular or atrial premature beats, Wolf-Parkinson-White syndrome. To avoid inclusion of patients undergoing atrioventricular junction ablation only (as a "pace and ablate" strategy), we excluded patients with cardiac implantable electronic device (CIED) in-situ. We also excluded patients who underwent CIED implantation or open surgical ablation during their hospitalization. Similar data extraction methodology was previously utilized to identify patients undergoing AF ablation in the NIS registry<sup>18,19</sup>.

The following patient demographics were collected from the database: age, sex, and ethnicity. ICD-10-CM codes and ICD-9-CM codes (Table S1) were used to identify different comorbidities, including diabetes, hypertension, chronic heart failure, chronic kidney disease, obstructive sleep apnea, obesity, chronic pulmonary disease, anemia, hypertrophic cardiomyopathy, valvular heart disease.

5

For the purposes of calculating the Charlson–Deyo comorbidity index, additional comorbidities were identified from the database using ICD-10-CM codes and ICD-9-CM codes. The Charlson–Deyo comorbidity index is a modification of the Charlson comorbidity index, containing 19 comorbidity conditions with differential weights, with a total score ranging from 0 to 38 <sup>20–22</sup>. Detailed information on Charlson–Deyo comorbidity index is provided in Table S2. Higher Charlson–Deyo comorbidity index scores indicate a greater burden of comorbid diseases and are associated with increased risk of death within 1 year after admission. The index has been used extensively in studies from administrative databases, with proven validity in predicting short-and long-term outcomes <sup>23–25</sup>. In addition, CHA<sub>2</sub>DS<sub>2</sub>-VASc and ATRIA bleeding scores were calculated for each patient.

We obtained information on the presence of a known malignancy for each patient, based on ICD-10-CM codes and ICD-9-CM codes outlined in Table S3. Malignancies were categorized into two groups: hematologic malignancies and solid malignancies.

The primary outcome in this study was in-hospital complications including death. Secondary outcomes included sub-groups of complications, as well as LOS and total charges. Using ICD-10-CM/ PCS codes and ICD-9-CM/PCS codes (Table S1) the following inhospital complications were identified: hemopericardium, tamponade, acute heart failure, cardiogenic shock, cardiac arrest, periprocedural hemorrhage/hematoma requiring transfusion, arteriovenous fistula, post procedure respiratory failure, periprocedural diaphragmatic disorder, periprocedural stroke and sepsis.

#### **Statistical Analysis**

Frequencies and proportions of the different demographic, clinical, and hospitalrelated variables were calculated and weighted to reflect national estimates using discharge sample weights provided by the NIS <sup>24</sup>. These estimates were compared according to

6

cancer/non-cancer grouping using the pearson's chi-square test and independent-samples ttest for categorical variables and continuous variables respectively. Generalized linear models were used to analyze annual trends. For all statistical analyses, we utilized SPSS® software version 23 (IBM Corp., Armonk, NY). A p-value < 0.05 was considered statistically significant.

#### RESULTS

A total of 13,583 hospitalizations for AF ablation across the United States during the study period were included in the analysis. After implementation of the weighting method, these represented an estimated total of 67,915 hospitalizations for AF ablation. Most patients (61%) were men, and the mean age of the cohort was  $64.4\pm10.9$  years. Of the total estimated cohort, 950 patients (1.4%) had a diagnosis of cancer.

Baseline characteristics of the study population according to cancer/non-cancer grouping are presented in detail in Table 1. Older age, male gender, heart failure, chronic kidney disease and anemia were more prevalent in the cancer group. In addition, cancer patients had both higher CHA<sub>2</sub>DS<sub>2</sub>-VASc ( $2.72 \pm 1.36$  vs.  $2.32 \pm 1.45$ , p<0.001) and ATRIA bleeding scores ( $1.91 \pm 1.86$  vs.  $1.21 \pm 1.37$ , p<0.001; Table 1).

Among cancer patients who underwent AF ablation during the study period, 495 (52%) had a solid malignancy, while 455 (48%) had a hematologic malignancy (Figure 1). Among solid malignancies, prostate cancer and lung cancer were most frequent, and leukemia was most frequent of the hematologic malignancies (Figure 1).

The annual trend of AF catheter ablations for cancer patients gradually increased from 1.05% (n=115) in 2012 to 2.03% (n=170) in 2019 (p<0.001; Figure 2).

#### In-Hospital Course and Outcomes by Cancer/Non-cancer groups

In-hospital complication occurred in 5400 patients (8%) admitted for AF ablation. Compared with those without cancer, patients who had a cancer diagnosis had higher unadjusted rate of total in-hospital complications (10.5% vs 7.9%, p<0.001). The higher complications rate in the cancer group was driven by increased rate of bleeding (3.2% vs 1.8%. p=0.002) and infectious complications (2.1% vs 0.8%, p<0.001; Table 2). No significant differences were observed in cardiac complications, periprocedural stroke and in-

hospital mortality rates, which were low in both groups (Table 2). The average LOS in the hospital was longer in cancer patients compared with non-cancer patients ( $4.91 \pm 5.8$  vs. 2.75  $\pm 3.05$ , Table 2).

Analysis of in-hospital complications by cancer type showed no significant difference in total complications rate between patients with solid or hematologic malignancies (10.1% vs 11%, p=0.36). However, patients with hematologic cancer had a significantly higher rate of bleeding complications, while those with solid cancer had higher rates of post-procedural respiratory failure and infectious complications (Figure 3).

#### DISCUSSION

Using data from the NIS, the largest all-payer inpatient database in the United States, we analyzed a weighted total of 67915 catheter ablation procedures for AF, between January 2012 and December 2019. Real-world nationwide data showed that 950 patients (1.4%) undergoing AF ablation had a cancer diagnosis. Annual trend analysis showed a gradual and significant increase of AF catheter ablations for cancer patients between 2012-2019. Cancer patients undergoing AF catheter ablation, were older, had more comorbidities and elevated thrombotic as well as bleeding risks, reflected by higher CHA<sub>2</sub>DS<sub>2</sub>-VASc and ATRIA bleeding indices, compared to their non-cancer counterparts. However, despite higher rate of total complications among cancer patients, driven by infectious and bleeding complications, no significant differences were observed in cardiac complications, periprocedural stroke or in-hospital mortality rates.

Current guidelines recommend pursuing rhythm control in symptomatic AF patients.<sup>1</sup> However, this may be challenging in cancer patients who also have AF. Maintaining sinus rhythm with anti-arrhythmic medications may involve significant drug-drug interactions with

anti-cancer agents <sup>8</sup>, There is scarce data on the efficacy of catheter ablation in this population. Nevertheless, observational data suggests that catheter ablation is equally effective in patients with or without a cancer history <sup>12,13</sup>.

Very few studies assessed the safety of AF catheter ablation in cancer patients with discrepant results. Giustozzi et al. showed higher risk for clinically relevant periprocedural bleeding compared to non-cancer patients in 21 cancer patients who underwent AF catheter ablation.<sup>11</sup> In two other studies, the frequency of periprocedural bleeding was similar between cancer and non-cancer patients <sup>12,13</sup>. Of note, different periprocedural anticoagulation protocols were utilized in these studies, as no such protocol was ever verified in cancer patients. In our analysis, cancer patients had a higher rate of bleeding complications compared to non-cancer patients. We do not have data on the anticoagulation regimen given during and after the ablation in our cohort. Notably, the excess bleeding we observed was in patients with hematologic malignancies, which constituted almost half of patients, a higher proportion than in previous studies <sup>9–13</sup>. In a retrospective analysis of patients undergoing percutaneous coronary interventions, leukemia diagnosis was associated with higher periprocedural bleeding complications <sup>26</sup>. Whether hematologic cancer patients are at higher risk for bleeding complications in AF ablations needs to be evaluated in future studies.

Infectious outcomes were not reported in prior studies of AF ablation in cancer patients, who are potentially immunocompromised, due to both disease and treatment <sup>5</sup>. In our study, we report for the first time a non-negligible rate of periprocedural infectious complications in cancer patients (2.1%), significantly higher than in non-cancer patients (0.5%). To date, there is no recommendation regarding periprocedural antibiotic prophylaxis for patients undergoing AF ablation <sup>27</sup>. Guidelines for vascular and interventional radiology procedures recommend against antibiotic prophylaxis in patients undergoing cardiac procedures (e.g. coronary angioplasty), but give a IIb indication for antibiotic prophylaxis in

10

patients undergoing solid tumor radiofrequency ablation, with the rationale being that thermal injury during this procedure may create a hospitable environment for bacteria <sup>28</sup>. Whether cancer patients undergoing AF ablation need periprocedural antibiotic prophylaxis should be evaluated in future studies.

Recently, Thotamgari et al. <sup>14</sup> evaluated AF ablation procedure outcomes in 750 cancer patients identified in the NIS database between years 2016-2019. Utilizing propensity score matching technique, they reported a higher in-hospital mortality rate in cancer patients compared with non-cancer patients (2% vs. 0.7%). Importantly, patients with in-situ CIEDs were not excluded from their analysis. There are no specific ICD 9/10 codes for AV node ablation, so it is possible that such procedures were included in their analysis. As AV node ablation is usually reserved for the older and sicker patients, <sup>1,16</sup> the possibility of selection bias resulting in an unsound signal of excess mortality is conceivable. This could potentially explain their discrepant results with ours as well as with previous studies.<sup>9–13</sup>

#### **Study strengths and limitations**

Several limitations should be acknowledged. The NIS database is a retrospective administrative database that contains discharge-level records and as such is susceptible to coding errors. Lack of information about patients' cancer status in the NIS prevents us from distinguishing between patients with active cancer and patients with inactive disease, as well as concurrent anti-neoplastic treatment. We could only capture events that occurred in the same index hospitalization as the NIS does not include any follow-up data and all data is intentionally non-identified. The NIS database also does not include detailed information about patients' clinical characteristics, medication, blood tests, and so on. These limitations are counterbalanced by the real-world, nationwide nature of the data, lack of selection bias, and absence of reporting bias introduced by selective publication of results from specialized

centers. These results should not infer causation of periprocedural risk by malignancy, but merely present real world association that requires randomized trials for validation.

#### CONCLUSIONS

The number of cancer patients undergoing AF catheter ablation procedures in the US increased steadily during the study period of 2012-2019. AF catheter ablation for cancer patients was associated with higher bleeding and infectious complication rates, but not with increased cardiac complications or in-hospital mortality in a nationwide, all-comer registry. These findings suggest that catheter ablation is a safe treatment modality for cancer patients who also experience AF.

Acknowledgments: None Source of Funding: None Disclosures: None. Supplemental Material

Tables S1-S3.

#### REFERENCES

- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42:373–498.
- Yun JP, Choi E-K, Han K-D, Park SH, Jung J-H, Park SH, Ahn H-J, Lim J-H, Lee S-R, Oh S. Risk of Atrial Fibrillation According to Cancer Type: A Nationwide Population-Based Study. *JACC CardioOncol.* 2021;3:221–232.
- Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. *Eur Heart J*. 2022;43:300–312.
- Conen D, Wong JA, Sandhu RK, Cook NR, Lee I-M, Buring JE, Albert CM. Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. *JAMA Cardiol.* 2016;1:389–396.
- Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. 2022 ESC Guidelines on cardiooncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022;43:4229–4361.

- 6. Guha A, Dey AK, Jneid H, Ibarz JP, Addison D, Fradley M. Atrial fibrillation in the era of emerging cancer therapies. *Eur Heart J*. 2019;40:3007–3010.
- Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. *J Am Coll Cardiol*. 2014;63:945–953.
- Asnani A, Manning A, Mansour M, Ruskin J, Hochberg EP, Ptaszek LM.
   Management of atrial fibrillation in patients taking targeted cancer therapies.
   *Cardiooncology*. 2017;3:2.
- Kanmanthareddy A, Vallakati A, Reddy Yeruva M, Dixit S, DI Biase L, Mansour M, Boolani H, Gunda S, Bunch TJ, Day JD, et al. Pulmonary vein isolation for atrial fibrillation in the postpneumonectomy population: a feasibility, safety, and outcomes study. *J Cardiovasc Electrophysiol*. 2015;26:385–389.
- Shabtaie SA, Luis SA, Ward RC, Karki R, Connolly HM, Pellikka PA, Kapa S, Asirvatham SJ, Packer DL, DeSimone CV. Catheter Ablation in Patients With Neuroendocrine (Carcinoid) Tumors and Carcinoid Heart Disease: Outcomes, Peri-Procedural Complications, and Management Strategies. *JACC Clin Electrophysiol*. 2021;7:151–160.
- Giustozzi M, Ali H, Reboldi G, Balla C, Foresti S, de Ambroggi G, Lupo PP, Agnelli G, Cappato R. Safety of catheter ablation of atrial fibrillation in cancer survivors. *J Interv Card Electrophysiol.* 2021;60:419–426.
- Eitel C, Sciacca V, Bartels N, Saraei R, Fink T, Keelani A, Gaßmann A, Kuck K-H,
   Vogler J, Heeger C-H, et al. Safety and Efficacy of Cryoballoon Based Pulmonary

Vein Isolation in Patients with Atrial Fibrillation and a History of Cancer. *J Clin Med*. 2021;10.

- Ganatra S, Abraham S, Kumar A, Parikh R, Patel R, Khadke S, Kumar A, Liu V, Diaz ANR, Neilan TG, et al. Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer. *Cardiooncology*. 2023;9:19.
- Thotamgari SR, Sheth AR, Patel HP, Sandhyavenu H, Patel B, Grewal US, Bhuiyan MAN, Dani SS, Dominic P. Safety of catheter ablation for atrial fibrillation in patients with cancer: a nationwide cohort study. *Postgrad Med.* 2023;1–7.
- López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez-Villanueva P, Escobar Cervantes C, Alonso Martín C, Alonso Salinas GL, Arenas M, et al. Atrial fibrillation in active cancer patients: expert position paper and recommendations. *Rev Esp Cardiol (Engl Ed)*. 2019;72:749–759.
- 16. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. *J Am Coll Cardiol*. 2019;74:104–132.
- Steiner C, Elixhauser A, Schnaier J. The healthcare cost and utilization project: an overview. *Eff Clin Pract*. 2002;5:143–151.
- Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, Grover P, Singh V,
   Vallurupalli S, Savani GT, et al. In-hospital complications associated with catheter

ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. *Circulation*. 2013;128:2104–2112.

- Rozen G, Elbaz-Greener G, Marai I, Andria N, Hosseini SM, Biton Y, Heist EK, Ruskin JN, Gavrilov Y, Carasso S, et al. Utilization and complications of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. *J Am Heart Assoc*. 2020;9:e015721.
- 20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol*. 1992;45:613–619.
- Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. *Am Health Drug Benefits*. 2019;12:188–197.
- 22. Chu Y-T, Ng Y-Y, Wu S-C. Comparison of different comorbidity measures for use with administrative data in predicting short- and long-term mortality. *BMC Health Serv Res.* 2010;10:140.
- Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, Puhan MA, Erne P, AMIS Plus Investigators. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. *Heart*. 2014;100:288–294.
- 24. Hosseini SM, Moazzami K, Rozen G, Vaid J, Saleh A, Heist KE, Vangel M, Ruskin JN. Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013. *Eur Heart J*. 2017;38:2122–2128.

- Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, Panageas KS, DeAngelis LM. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. *Blood*. 2019;133:781–789.
- Potts J, Mohamed MO, Lopez Mattei JC, Iliescu CA, Konopleva M, Rashid M, Bagur R, Mamas MA. Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis. *Catheter Cardiovasc Interv*. 2020;96:53–63.
- 27. Calkins H, Hindricks G, Cappato R, Kim Y-H, Saad EB, Aguinaga L, Akar JG,
  Badhwar V, Brugada J, Camm J, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE
  expert consensus statement on catheter and surgical ablation of atrial fibrillation:
  Executive summary. *Heart Rhythm.* 2017;14:e445–e494.
- 28. Chehab MA, Thakor AS, Tulin-Silver S, Connolly BL, Cahill AM, Ward TJ, Padia SA, Kohi MP, Midia M, Chaudry G, et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. *J Vasc Interv Radiol.* 2018;29:1483-1501.e2.

#### **Figure legends**

Figure 1: Cancer distribution by solid/hematologic malignancy

NE= national estimate of hospitalizations.

Figure 2: Annual trend of AF catheter ablations for cancer patients between 2012-2019.

Figure 3: In-hospital complications by cancer type

Variable	Non-cancer Patients	Cancer Patients	р
	(n=66965)	(n=950)	value
Age (years)	64± 11	$69 \pm 9$	< 0.001
Female	26140 (39%)	310 (33%)	< 0.001
White ethnicity	57250 (86%)	840 (88%)	0.006
Diabetes mellitus	13945 (21%)	225 (24%)	0.017
Hypertension	38265 (57%)	500 (53%)	0.003
Heart failure	16585 (25%)	370 (39%)	< 0.001
Valvular heart disease	8385 (13%)	140 (15%)	0.023
Chronic kidney disease	6655 (10%)	170 (18%)	< 0.001
Chronic Pulmonary Disease	9875 (15%)	195 (21%)	< 0.001
Obesity (BMI>30)	15430 (23%)	215 (23%)	0.398
Obstructive sleep apnea	14985 (22%)	190 (20%)	0.044
Prior stroke	1155 (1.7%)	15 (1.6%)	0.414
Prior myocardial infarction	3760 (6%)	60 (6%)	0.003
Hypertrophic cardiomyopathy	610 (0.9%)	None	NA
Peripheral artery disease	2670 (4%)	55 (6%)	0.003
Anemia	4000 (6%)	195 (21%)	< 0.001
Charlson comorbidity index $\geq 2$	15700 (24%)	900 (95%)	< 0.001
CHA2DS2 VASc score	$2.32 \pm 1.45$	$2.72 \pm 1.36$	< 0.001
0-1	21455 (32%)	185 (19%)	< 0.001
<u>≥</u> 2	45510 (68%)	765 (81%)	

#### Table 1: Baseline characteristics of patients undergoing AF catheter ablation

ATRIA bleeding score	$1.21 \pm 1.37$	$1.91 \pm 1.86$	< 0.001
0-1	51130 (76%)	520 (55%)	< 0.001
≥2	15835 (24%)	430 (45%)	
Income percentile			
0–25	13700 (21%)	150 (16%)	0.001
26–50	15540 (23%)	255 (27%)	
51–75	17610 (26%)	240 (25%)	
76–100	20115 (30%)	305 (32%)	
Teaching hospital	55000 (82%)	770 (81%)	0.206
Hospital region			
South/west	37900 (57%)	515 (54%)	0.075
Midwest/northeast	29065 (43%)	435 (46%)	

Table 2: In-hospital diagnoses and procedures of patients undergoing AF catheter ablation with/ without cancer

Variable	Non-cancer Patients	<b>Cancer Patients</b>	р
	(n=66965)	(n=950)	value
Total complications	5300 (7.9%)	100 (10.5%)	0.002
Cardiac complications			
Cardiogenic shock	80 (0.1%)	None	NA
Cardiac arrest	100 (0.1%)	None	NA
Acute heart failure	445 (0.7%)	<u>&lt;</u> 10	NA
Hemopericardium/cardiac	1085 (1.6%)	<u>&lt;</u> 10	NA
tamponade			
Vascular complications			
Hemorrhage/hematoma/blood	1230 (1.8%)	30 (3.2%)	0.002
transfusion			
Vascular injury	1065 (1.6%)	15 (1.6%)	0.557
<b>Respiratory complications</b>			
Post-procedural respiratory	1125 (1.6%)	20 (2.1%)	0.188
failure/invasive ventilation			
>24 hrs			
Diaphragmatic disorders	190 (0.2%)	None	NA
Neurologic complications	95 (0.1%)	<u>&lt;</u> 10	NA
(stroke)			
Infectious complications	530 (0.8%)	20 (2.1%)	< 0.001
(bacteremia, sepsis)			

Length of stay	2.75 <u>+</u> 3.05	4.91 <u>+</u> 5.8	< 0.001
In-hospital mortality	165 (0.2%)	<u>&lt;</u> 10	NA

## Cancer distribution by solid/hematologic malignancy (n=950)



\*Thyroid, Connective tissue, Gynecological, Neuro Endocrine Tumor. Melanoma, Head and Neck

## Annual trends of AF ablation admissions in cancer patients in the US



# In-hospital complications by cancer type (n=950)

